Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Posatex Otic Suspension Patent Expiration

Posatex Otic Suspension is a drug owned by INTERVET, INC. It is protected by 8 US drug patents filed from 2014 to 2029. Out of these, 2 patents are active and 6 patents have expired. Details of Posatex Otic Suspension’s patents and their expiration are given below.

Filter patents by

Country : United States (US)
Patent Category : All
Drug Patent Number Drug Patent Expiry Status
Patent Data
US8609645 10 Aug, 2025 Expired
US6958337 05 Oct, 2018 Expired
US6713481 05 Oct, 2018 Expired
US6127353 03 Oct, 2017 Expired
US5661151 26 Aug, 2014 Expired
US5703073 26 Aug, 2014 Expired

Exclusivity Information

Posatex Otic Suspension holds 1 exclusivity out of which 1 has expired. Details of Posatex Otic Suspension's exclusivity codes and their expiration dates are given below.

Drug Exclusivity Drug Exclusivity Expiration
NCI Feb 18, 2013

About Posatex Otic Suspension

Posatex Otic Suspension is a drug owned by INTERVET, INC. Posatex Otic Suspension uses Mometasone Furoate Monohydrate, Orbifloxacin, Posaconazole as the active ingredients.

Active Ingredient:

Posatex Otic Suspension uses Mometasone Furoate Monohydrate, Orbifloxacin, Posaconazole as the active ingredients. Check out other Drugs and Companies using Mometasone Furoate Monohydrate, Orbifloxacin, Posaconazole ingredient.